Microdosing and Macrodosing Ketamine: What the Labels Leave Out

“Microdosing” and “macrodosing” appear frequently in ketamine marketing, but they do not give patients a complete or reliable description of a medical treatment. Before comparing these labels, ask about the exact medication, route, prescribed dose, frequency, and monitoring plan.

Compounded ketamine is not FDA-approved. FDA has not reviewed compounded medications for safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric disorders. Compounded ketamine nasal spray is different from Spravato, the FDA-approved esketamine product used in certified healthcare settings.

A label cannot replace a prescription

Do not assume that “microdosing” means a dose is free of dissociation, impairment, misuse risk, or other adverse effects. Likewise, an intense experience described as a “macrodose” does not establish that treatment is more effective. The appropriate clinical question is whether the proposed plan is justified for your situation.

Amount, concentration, and volume are different measurements. A spray, tablet, or infusion cannot be compared simply by counting administrations. Ask your clinician and pharmacist to explain your label and device. Do not convert another person’s prescription into your own dose or adjust the frequency yourself.

What does the evidence actually measure?

A study may examine a particular route in a monitored clinic, enroll a selected group of patients, and follow them for a limited period. Its findings cannot establish what a different compounded at-home formulation will do. Ask for evidence about the actual treatment being proposed, including what remains uncertain.

Claims that a smaller dose continually improves neuroplasticity, or that a larger dose creates a necessary emotional breakthrough, should not be taken as proof of clinical benefit. Feeling detached or experiencing altered perception is a drug effect that should be discussed, not a treatment goal to pursue independently.

Questions for Texas and California patients

• What is the clinical reason for this formulation and schedule?
• Which alternatives have stronger evidence for my diagnosis?
• What monitoring is needed during and after administration?
• How will we assess benefit and unwanted effects over time?
• What should prompt me to contact you before another dose?

Tell the clinician about other prescriptions, over-the-counter products, alcohol, and other substances. Discuss activities requiring alertness, including driving and work duties. A convenient schedule should not determine whether a medication or setting is medically appropriate.

Risks and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, increased blood pressure, and slowed breathing. Other concerns include abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems. A prescription or lower dose does not eliminate these risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Virtual follow-up does not provide the same monitoring as an onsite team. Discuss whether the setting is appropriate, your medication interactions, and an emergency plan before treatment.

Discuss your questions with a clinician

Bliss Mist Rx LLC provides telehealth services and does not compound or manufacture medications. If treatment is prescribed, an independent, appropriately licensed compounding pharmacy dispenses the medication. A consultation does not guarantee a prescription; applicable prescribing and compounding requirements must be met.

Book a Free Virtual Appointment or Follow-Up to review your questions, alternatives, and next steps. This article provides general education and does not replace individualized medical advice.

Further reading: FDA: compounded-drug risks; FDA: compounding risk alerts.